SVRA — Savara Inc

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1160308 ·
Last close
$4.48
Market Cap
$988.39M
52W High
$7.01
52W Low
$4.13
ADV30
2,788,158
Next earnings
2026-11-11
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. was founded in 2007 and is headquartered in Yardley, Pennsylvania.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -43,542,000 -42,989,000 155,933,000 29,812,000 48,083,000
Jun 2026 0 — -40,965,000 -40,228,000 192,138,000 41,800,000 48,478,000
Mar 2026 0 — -38,137,000 -37,284,000 221,645,000 38,791,000 45,606,000
Dec 2025 0 — -33,419,000 -32,236,000 253,436,000 33,180,000 50,303,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-130,314,000
Investing CF
$8,825,000
Financing CF
$135,169,000
CapEx
$-631,000
Dividends Paid
—
Buybacks
$-5,434,000
EPS Diluted TTM
$-0.62
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-728,588,000
Inventory
—
Receivables
$1,117,000
ST Investments
$99,837,000
EBIT TTM
$-156,063,000
Pretax Income TTM
$-152,737,000
Interest Exp TTM
—
Analysts
9

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -122,763,000 -118,837,000 253,436,000 50,303,000 203,133,000 -101,037,000
Dec 2024 0 -102,399,000 -95,881,000 212,879,000 41,430,000 171,449,000 -89,088,000
Dec 2023 0 -59,210,000 -54,698,000 177,564,000 37,192,000 140,372,000 -51,061,000
Dec 2022 0 -38,043,000 -38,150,000 139,777,000 31,999,000 107,778,000 -34,554,000

TTM Snapshot

Revenues TTM
$0
NetIncome TTM
$-139,309,000
OpCashFlow TTM
—
Assets (Latest)
$192,138,000
Forward EPS
$-0.37

Max Pain — expiry 2026-12-18 (volume-derived — Yahoo OI feed degraded)

max pain strike: $4.00 · spot: $4.72 · call volume: 1,006 · put volume: 245
Expected Move to 2026-12-18: ±$2.17 (45.97%) — implied range $2.55 – $6.89 · ATM straddle on $5.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
JBIO Jade Biosciences, Inc. $979.40M $15.40 —
ANRO Alto Neuroscience, Inc. $999.16M $24.91 —
CYRX Cryoport, Inc. $999.81M $19.74 —
SPTX Seaport Therapeutics, Inc. $972.65M $18.17 —
OMER OMEROS CORP $1.01B $13.92 —

News headlines (Yahoo Finance, 1h cache)

FDA Decision Watch: Capricor’s DMD Therapy Faces Make-Or-Break Decision, Savara’s Lung Disease Drug In The Spotlight This Week
2026-11-16 10:09 · Yahoo
Savara Announces New Employment Inducement Grant
2026-11-12 21:05 · Yahoo
Savara Presented New Data Showing Molgramostim Inhalation Solution (Molgramostim) Treatment Effects in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Patients with Mild Diffusion Impairment
2026-10-21 17:10 · Yahoo
Will Long‑Term Molgramostim Data at CHEST 2026 Change Savara's (SVRA) Autoimmune PAP Narrative?
2026-10-13 08:14 · Yahoo
Savara to Present New Analysis from the IMPALA Clinical Trial and Deliver Encore Presentation of Long-Term Data on Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at CHEST 2026
2026-10-12 20:05 · Yahoo
Savara Has Lost 30% Since December: JPMorgan Sees 146% Upside
2026-10-11 16:43 · Yahoo
Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the European
2026-08-24 20:05 · Yahoo
Savara Reports Second Quarter 2026 Financial Results and Provides Business Update
2026-08-11 20:05 · Yahoo
Savara Announces European and Australian Patent Offices Have Granted Patents for the Liquid Formulation of MOLBREEVI*, Providing Protection in Europe and Australia Until March 2041
2026-07-30 12:05 · Yahoo
Here's Why You Should Add Savara Stock to Your Portfolio Now
2026-07-22 13:21 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.